Galectin 9 anticorps (AA 200-355)

N° du produit ABIN8093295

Cet anticorps anti-Galectin 9 Monoclonal Souris (Clone LGALS9-7689) (ABIN8093295) détecte spécifiquement Galectin 9 dans IHC. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Galectin 9 anticorps (AA 200-355) (ABIN8093295)

Antigène: Galectin 9 (LGALS9) (Lectin, Galactoside-Binding, Soluble, 9 (LGALS9))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Galectin 9 est non-conjugé

Application: Immunohistochemistry (IHC)

Clone: LGALS9-7689

Détail du produit anti-Galectin 9 anticorps

Épitope: AA 200-355

Fonction: LGALS9 Antibody / Galectin 9

Immunogène: A recombinant fragment (around amino acids 200-355) of human LGALS9 protein (exact sequence is proprietary) was used as the immunogen for the LGALS9/Galectin 9 antibody.

Isotype: IgG2, kappa

Information d'application

Indications d'application: Optimal dilution of the LGALS9/Galectin 9 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.05 % BSA, 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: LGALS9/Galectin 9 antibody with sodium azide - store at 2 to 8oC, antibody without sodium azide - store at -20 to -80oC.

Détails sur Galectin 9

Antigène: Galectin 9 (LGALS9) (Lectin, Galactoside-Binding, Soluble, 9 (LGALS9))

Autre désignation: LGALS9

Sujet: LGALS9 Antibody recognizes Galectin 9, also known as Lectin galactoside-binding soluble 9, a beta-galactoside-binding lectin encoded by the LGALS9 gene. Galectin 9 antibody is widely referenced in immunology literature as LGALS9 antibody and Gal-9 antibody due to its established role in immune regulation and tumor immunology. Galectin 9 belongs to the galectin family of carbohydrate-binding proteins characterized by conserved carbohydrate recognition domains that bind beta-galactoside-containing glycoconjugates.

Galectin 9 is expressed in a variety of immune and epithelial cell types and can localize to the cytoplasm, nucleus, and extracellular space depending on cellular context. Structurally, Galectin 9 contains two tandem carbohydrate recognition domains connected by a linker peptide, allowing it to crosslink glycoproteins on the cell surface. This structural organization enables Galectin 9 to modulate cell adhesion, apoptosis, and immune checkpoint signaling pathways. LGALS9 antibody is commonly used in studies evaluating Galectin 9 expression in inflammatory diseases, viral infections, and cancer microenvironments.

Functionally, Galectin 9 is best known for its interaction with immune regulatory receptors such as TIM-3, influencing T cell exhaustion, tolerance, and immune homeostasis. Through these interactions, Galectin 9 participates in the regulation of innate and adaptive immune responses. Altered expression of LGALS9 has been reported in multiple tumor types, where Galectin 9 expression may correlate with immune infiltration and tumor immune evasion mechanisms. As a result, Galectin 9 antibody is frequently utilized in tumor immunology and biomarker research settings.

Beyond immune modulation, Galectin 9 has been implicated in cell aggregation, apoptosis induction, and regulation of cytokine production. Differential expression patterns across tissues and disease states make LGALS9 Antibody a valuable tool for examining Galectin 9 distribution and its role in immune checkpoint biology, inflammatory signaling, and cancer-associated immune landscapes.

UniProt: O00182